Stoke Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Stoke Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2023.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $7.43M, a 9.87% increase year-over-year.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $25.4M, a 4.45% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.3M, a 10.5% increase from 2022.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.9M, a 38.9% increase from 2021.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $16.5M, a 185% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $25.3M +$2.4M +10.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-25
2022 $22.9M +$6.4M +38.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-25
2021 $16.5M +$10.7M +185% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-06
2020 $5.77M +$3.85M +200% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $1.92M +$1.68M +701% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 $240K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.